Core Viewpoint - Zhixiang Jintai (688443.SH) forecasts a net loss attributable to shareholders of the parent company for 2025, estimated between -480.64 million to -587.45 million yuan, representing a year-on-year reduction in losses by 209.83 million to 316.64 million yuan, or a decrease of 26.32% to 39.71% compared to the previous year [1] Group 1: Financial Performance - The company's operating revenue has significantly increased compared to the same period last year, primarily due to steady sales growth of its first commercial product, Saliqi monoclonal antibody injection (Jinlixi®), and revenue from the licensing agreement for GR1803 injection [1] - The forecasted net loss for 2025 indicates a substantial improvement in financial performance compared to the previous year [1] Group 2: Research and Development - The company continues to focus on original innovation and efficiently advancing the progress of various research projects, with multiple products entering clinical research and core products entering critical clinical trial phases [1] - The company maintains a high level of R&D investment in its ongoing projects, reflecting its commitment to innovation [1] - The stock incentive plan implemented for the core team in 2022 will expire in 2024, resulting in a reduction of corresponding expenses in 2025 [1]

每经AI快讯，康泰生物1月29日晚间发布业绩预告，预计2025年归属于上市公司股东的净利润4900万元 ~7300万元，同比下降63.8%~75.7%。 （记者 曾健辉） 每经头条（nbdtoutiao）——水贝黄金平台"杰我睿"兑付危机调查：40倍杠杆对赌，金价越涨平台越 亏！老板自称"还在深圳"，投资者：兑付方案本金打两折，无法接受 ...

Core Viewpoint - The company expects a significant decline in net profit for 2025, projecting a range between 49 million to 73 million yuan, representing a year-on-year decrease of 63.8% to 75.7% [1] Group 1: Financial Performance - The company reported a slight increase in operating revenue compared to the previous year [1] - The overseas business generated revenue of 98.8353 million yuan, marking a substantial year-on-year increase of 859.4% [1] Group 2: Strategic Initiatives - The company is enhancing market promotion and qualification work for new products, including freeze-dried human rabies vaccine and varicella live attenuated vaccine, to improve market share of core products [1] - The company is steadily advancing its international strategy and expanding its overseas business layout [1]

格隆汇1月29日丨特宝生物(688278.SH)公布，公司于近日获得工业和信息化部颁发的《制造业单项冠军 企业证书》，公司凭借聚乙二醇干扰素α-2b注射液（商品名：派格宾）的产品技术优势和市场地位被认 定为工业和信息化部第九批制造业单项冠军企业。 ...

1.报告期内，预计实现的营业收入与上年同期基本持平，主要系公司生物制品类产品增值税率由3%调 整至13%，对整体营收与盈利产生不利影响。2.报告期内，公司积极应对外部环境变化影响，加强技术 与产品研发，优化降本增效举措，提升经营效率，不断巩固公司科技创新实力与市场竞争力。同时，公 司保持市场投入强度，积极拓展创新业务与海外市场，销售费用同比有所增长，对当期经营结果有一定 不利影响。3.报告期内，公司基于实际情况与审慎性原则，计提了部分信用减值损失和资产减值损失， 亦对当期经营结果产生一定不利影响。 格隆汇1月29日丨诺唯赞(688105.SH)公布，预计公司2025年度实现归属于母公司所有者的净利润-2,000 万元至-1,000万元。 实现归属于母公司所有者的扣除非经常性损益的净利润-8,500万元至-7,000万元。 2025年度，公司预计出现亏损，主要原因如下： （原标题：诺唯赞(688105.SH)：2025年度预亏1000万元至2000万元） ...

本文源自：市场资讯 作者：公告君 有投资者在互动平台向纳微科技提问："从海外业务来源地区看，已有欧盟国家的药物应用项目，请问 欧盟地区业务收入在公司整体营业收入中的占比大致为多少？此外，公司对欧盟市场的销售主要通过哪 种方式实现？是以境内主体直接向欧盟客户出口为主，还是通过在欧盟国家设立的子公司进行销售，或 通过第三方贸易商、代理商转销至欧盟市场？" 针对上述提问，纳微科技回应称："尊敬的投资者，您好！公司通过完善海外营销体系，加强海外销售 力量，增加与战略合作伙伴的合作等措施，推动海外业务快速增长。目前，欧洲市场的业务拓展采取公 司直接提供应用技术服务和直销供应的方式实现，主要由公司的国际业务团队负责。公司在《2025年年 度业绩预告的自愿性披露公告》中披露，2025年度公司实现国际业务收入约8,400万元，同比增长约 79%，其中，来自欧盟国家的药物应用项目收入也实现快速增长，但在公司整体收入中的占比不高。谢 谢！" 声明：市场有风险，投资需谨慎。本文为AI基于第三方数据生成，仅供参考，不构成个人投资建议。 ...

每经AI快讯，1月29日，万泰生物（603392）(603392.SH)公告称，预计2025年归属于上市公司股东的净 利润为-4.10亿元至-3.30亿元，上年同期盈利1.06亿元，同比转亏。主要因二价HPV疫苗受集采降价、消 费需求不足等影响，出现近效期无法销售及库存减值，预计影响净利润约5亿–6亿元；九价HPV疫苗虽 已上市并加速准入，但报告期内利润贡献尚未充分体现；诊断板块亦受集采降价及医保政策影响，收入 利润同比下滑。 ...

南财智讯1月29日电，诺唯赞发布年度业绩预告，预计2025年全年归属于上市公司股东的净利润为-2000 万元至-1000万元；预计2025年全年归属于上市公司股东的扣除非经常性损益的净利润为-8500万元 至-7000万元。2025年度，公司预计出现亏损，主要原因如下：报告期内，预计实现的营业收入与上年 同期基本持平，主要系公司生物制品类产品增值税率由3%调整至13%，对整体营收与盈利产生不利影 响；报告期内，公司积极应对外部环境变化影响，加强技术与产品研发，优化降本增效举措，提升经营 效率，不断巩固公司科技创新实力与市场竞争力。同时，公司保持市场投入强度，积极拓展创新业务与 海外市场，销售费用同比有所增长，对当期经营结果有一定不利影响；报告期内，公司基于实际情况与 审慎性原则，计提了部分信用减值损失和资产减值损失，亦对当期经营结果产生一定不利影响。 ...

Core Viewpoint - The stock of Zhifei Biological has shown fluctuations, with a recent increase of 2.07% on January 29, 2023, despite a year-to-date decline of 3.39% [1] Group 1: Stock Performance - As of January 29, 2023, Zhifei Biological's stock price was 18.23 yuan per share, with a trading volume of 5.20 billion yuan and a turnover rate of 2.08%, resulting in a total market capitalization of 436.39 billion yuan [1] - The stock has experienced a 7.05% increase over the last five trading days, but a decline of 3.95% over the last 20 days and 14.37% over the last 60 days [1] Group 2: Financial Performance - For the period from January to September 2025, Zhifei Biological reported an operating income of 76.27 billion yuan, a year-on-year decrease of 66.53%, and a net profit attributable to shareholders of -12.06 billion yuan, reflecting a year-on-year decrease of 156.10% [2] Group 3: Shareholder Information - As of January 20, 2023, the number of shareholders for Zhifei Biological was 121,000, a decrease of 1.56% from the previous period, with an average of 11,686 circulating shares per person, an increase of 1.58% [2] - The company has distributed a total of 73.18 billion yuan in dividends since its A-share listing, with 31.94 billion yuan distributed in the last three years [3] Group 4: Institutional Holdings - As of September 30, 2025, major shareholders include Hong Kong Central Clearing Limited, holding 33.56 million shares, and several ETFs, all of which have seen a decrease in holdings compared to the previous period [3]

Group 1 - The monkeypox sector experienced a decline, with companies such as Da An Gene hitting the daily limit down, while Capstone Bio, Bohui Innovation, Hefei China, Kehua Bio, Zhijiang Bio, and Wanfeng Bio also saw declines [1]